Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -32724.20% is 882% below its 1-year average of -3331.69%, near the low end of its 1-year range (-32724.20%–0.00%).
882.21% below its 12-month average of -3331.69%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-32724.20%
NET PROFIT MARGIN AVG TTM
-3331.69%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-882.21%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Oculis Holding AG
Market Cap
$496.80M
Net Profit Margin
-32724.20%
TTM Avg
-3331.69%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$487.98M
Net Profit Margin
-10.85%
TTM Avg
-18.16%
3Y Avg
-29.23%
5Y Avg
-75.36%
Market Cap
$486.34M
Net Profit Margin
11.55%
TTM Avg
13.38%
3Y Avg
8.98%
5Y Avg
-0.37%
Market Cap
$510.79M
Net Profit Margin
-3566.68%
TTM Avg
-585431.82%
3Y Avg
-433391.80%
5Y Avg
-288954.46%
Market Cap
$509.60M
Net Profit Margin
-56.68%
TTM Avg
-93.15%
3Y Avg
-82.60%
5Y Avg
-71.77%
Market Cap
$509.02M
Net Profit Margin
-1371.51%
TTM Avg
-709.80%
3Y Avg
-108166.39%
5Y Avg
-73106.10%
Market Cap
$477.13M
Net Profit Margin
2.94%
TTM Avg
-53.14%
3Y Avg
-197.29%
5Y Avg
-267.69%
Market Cap
$515.36M
Net Profit Margin
-296000.00%
TTM Avg
-345077.99%
3Y Avg
-146585.06%
5Y Avg
-98190.17%
Market Cap
$475.60M
Net Profit Margin
-3.06%
TTM Avg
-9.59%
3Y Avg
-17.39%
5Y Avg
-29.37%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $496.80M | -32724.20% | -3331.69% | 0.00% | 0.00% |
| Evolus, Inc. (EOLS)vs › | $487.98M | -10.85% | -18.16% | -29.23% | -75.36% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.34M | 11.55% | 13.38% | 8.98% | -0.37% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.79M | -3566.68% | -585431.82% | -433391.80% | -288954.46% |
| 908 Devices Inc. (MASS)vs › | $509.60M | -56.68% | -93.15% | -82.60% | -71.77% |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.02M | -1371.51% | -709.80% | -108166.39% | -73106.10% |
| Arvinas, Inc. (ARVN)vs › | $477.13M | 2.94% | -53.14% | -197.29% | -267.69% |
| Altimmune, Inc. (ALT)vs › | $515.36M | -296000.00% | -345077.99% | -146585.06% | -98190.17% |
| Cerus Corporation (CERS)vs › | $475.60M | -3.06% | -9.59% | -17.39% | -29.37% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
-32724.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | -6936.21% |
| 2025-06-30 | -9722.22% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -3944.15% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
